Products
The Radiopharmaceutical industry leader in Korea
A fast growing biotech company with proven records
Radiopharmaceuticals
FP-CIT
| Indication | Diagnosis of Parkinson's disease and Parkinson's syndrome by measuring the density of dopamine carriers in the brain striatum |
|---|---|
| Features | World's first brain imaging tracer related to Parkinson's disease *DuChemBio owns all FP-CIT license and rights for the technology & clinical data package worldwide except Korea |
F-DOPA
| Indication | Diagnosis of tumors that cannot be diagnosed with conventional FDG, mainly brain tumors and additionally neuroendocrine tumors, pheochromocytoma |
|---|---|
| Features | The world's first Radiopharmaceutical for brain tumor diagnosis with neutralization technology |
FES
| Indication | Diagnosis of metastatic breast cancer and determination of estrogen receptor status |
|---|---|
| Features | The world's first Radiopharmaceutical for breast cancer diagnosis |
FACBC
| Indication | Diagnostic imaging of recurrent or metastatic prostate cancer |
|---|---|
| Features | Radiopharmaceutical for prostate cancer diagnosis |
FDG
| Indication | Diagnosis of tumors that metabolize glucose |
|---|---|
| Features | Radiopharmaceuticals for the diagnosis of tumors, which contributed to the birth of the Radiopharmaceutical industry |
Neuraceq
| Indication | Diagnosis of Alzheimer's Disease by measurement of beta-amyloid distribution and density in the brain |
|---|---|
| Features | First Radiopharmaceutical in Asia for diagnosis of beta amyloid in Alzheimer's disease which is essential for differentiation from vascular dementia |
NaF
| Indication | Diagnostic imaging of bone to identify altered osteogenic active areas |
|---|---|
| Features | Radiopharmaceutical for the diagnosis of bone-related diseases |
177Lu-DOTATOC
| Indication | Treatment of inoperable neuroendocrine tumors originating from the GI tract and pancreas |
|---|---|
| Features | Korea’s first therapeutic Radiopharmaceutical for neuroendocrine tumors |
